Antibody

368개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved368 programs
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

N-803 + Avelumab + PD-L1 t-haNK (N-803 + Avelumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Docetaxel + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, N-803 + Docetaxel + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

durvalumab (Imfinzi, N-803 + Durvalumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

nivolumab (Opdivo, N-803 + Nivolumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, N-803 + Nivolumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

pembrolizumab (Keytruda, N-803 + Pembrolizumab + PD-L1 t-haNK)

Non-Small Cell Lung Cancer; Small Cell Lung Cancer · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

nivolumab (Opdivo, NAI + Nivolumab + Ipilimumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
AntibodyLimited DatastaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, NAI + Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#monoclonal-antibody#ImmunityBio
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

NUC-3373 + bevacizumab (NUC-3373 + bevacizumab)

Colorectal Cancer; Colorectal Neoplasms · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ColorectalNeoplasms+1
Trials 1Status Active
AntibodyLimited DatastaleNeoTX Therapeutics Ltd.Phase 1

durvalumab (Imfinzi, Naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#ER+BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

pembrolizumab (Keytruda, Neoadjuvant Pembrolizumab)

Breast Cancer; Triple Negative Breast Cancer (TNBC) · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleSwiss Cancer InstitutePhase 2

durvalumab (Imfinzi, Neoadjuvant and adjuvant durvalumab)

Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#Antibody#Phase2#monoclonal-antibody#Swiss
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Neoadjuvant chemotherapy combined with Toripalimab (Neoadjuvant chemotherapy combined with Toripalimab)

TNBC, Triple Negative Breast Cancer · TNBC, Triple Negative Breast Cancer

#TNBCTripleNegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#TNBC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Neoadjuvant chemotherapy+Durvalumab+Tremelimumab)

Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IV · Ovarian Cancer Stage IIIC

#OvarianCancerStageIIIC#Antibody#Phase2#monoclonal-antibody#OvarianCancerStageIV+1
Trials 1Status Active
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

Neoadjuvant ipilimumab (Neoadjuvant ipilimumab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

nivolumab (Opdivo, Neoadjuvant nivolumab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

Neoadjuvant relatlimab (Neoadjuvant relatlimab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting

12 / 19 pages

← PreviousNext →